Sicor Biotech orders biotech facility from Pharmadule

Published: 10-Mar-2010

Pharmadule has signed a contract with Sicor Biotech for the delivery of a biotech facility.


Pharmadule, a Swedish manufacturer of high-tech modular facilities for the pharmaceutical and biopharmaceutical industries, has signed a contract with Sicor Biotech for the delivery of a biotech facility.

Pharmadule will design, build, install and validate a complete biotech production facility for the company, a division of the Teva Group based in Vilnius, Lithuania.

Pharmadule's modular concept allows 80% of the construction to be completed in its own workshop, which the firm says results in a high and predictable quality, a short delivery schedule and financial benefits for customers.

The facility will be delivered to Sicor Biotech's site for installation, qualification and hand over to the client by January 2011. It will be delivered according to EU and US quality standards and is Sicor Biotech's second biotech facility from Pharmadule.

Sicor Biotech develops and manufactures recombinant biopharmaceuticals. Products include Realdiron (interferon alfa-2b human recombinant) registered in 18 countries, Biosoma (recombinant human growth hormone) registered in 11 countries, and Grasalva (filgrastim) recently registered in Lithuania.

Pharmadule has since 1986 delivered more than 60 manufacturing facilities to the pharmaceutical and biopharmaceutical industries worldwide, including to several multinational companies such as Eli Lilly, Merck, Baxter, GSK, Genentech, Pharmacia and AstraZeneca.

Pharmadule is headquartered in Stockholm and has engineering facilities in Gothenburg and Stockholm, manufacturing in Estonia and China, and sales and representative offices located globally.

You may also like